PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells
Authors
Keywords
Neuroblastoma, MK2206, Akt, PDK1, mTOR, Cell growth
Journal
Cancer Cell International
Volume 15, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-09-29
DOI
10.1186/s12935-015-0239-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children’s Oncology Group study
- (2015) L L Wang et al. BRITISH JOURNAL OF CANCER
- GSK-3 as potential target for therapeutic intervention in cancer
- (2015) James A. McCubrey et al. Oncotarget
- The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential
- (2014) Himisha Beltran MOLECULAR CANCER RESEARCH
- A phase I trial of MK-2206 in children with refractory malignancies: A Children's Oncology Group study
- (2014) Maryam Fouladi et al. PEDIATRIC BLOOD & CANCER
- The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro
- (2013) Qiang Li et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014
- (2013) Kurt G. Pike et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
- (2013) Howard A. Burris CANCER CHEMOTHERAPY AND PHARMACOLOGY
- mTOR inhibitors in advanced breast cancer: Ready for prime time?
- (2013) Lesley-Ann Martin et al. CANCER TREATMENT REVIEWS
- Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
- (2013) Jiri Polivka et al. PHARMACOLOGY & THERAPEUTICS
- PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
- (2012) F. Janku et al. CANCER RESEARCH
- Combination of an Allosteric Akt Inhibitor MK-2206 with Etoposide or Rapamycin Enhances the Antitumor Growth Effect in Neuroblastoma
- (2012) Z. Li et al. CLINICAL CANCER RESEARCH
- 246 Aberrations in PIK3CA, PTEN, and MAPK (KRAS, NRAS, BRAF) in 1,656 Patients and Experience with Early-phase Protocols with PI3K/AKT/mTOR Inhibitors
- (2012) F. Janku et al. EUROPEAN JOURNAL OF CANCER
- PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations
- (2012) Filip Janku et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice
- (2011) M. E. Balasis et al. CLINICAL CANCER RESEARCH
- The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAFV600EInhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells
- (2011) Ruixin Liu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Disruption of the AKT pathway inhibits metastasis in an orthotopic model of head and neck squamous cell carcinoma
- (2011) Joseph A. Knowles et al. LARYNGOSCOPE
- MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis
- (2011) Y. Cheng et al. MOLECULAR CANCER THERAPEUTICS
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program
- (2011) Richard Gorlick et al. PEDIATRIC BLOOD & CANCER
- For a PDK1 inhibitor, the substrate matters
- (2010) Zachary A. Knight BIOCHEMICAL JOURNAL
- Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1
- (2010) Ayaz Najafov et al. BIOCHEMICAL JOURNAL
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
- (2009) C. M. Chresta et al. CANCER RESEARCH
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- The nuts and bolts of AGC protein kinases
- (2009) Laura R. Pearce et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer
- (2008) David F. Stern JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Class I PI3K in oncogenic cellular transformation
- (2008) L Zhao et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now